What “abrocitinib process synthesis” patents are likely to cover
A “process synthesis” patent for abrocitinib typically focuses on how to make the molecule (not the compound itself). Such filings often claim one or more steps or a specific sequence for forming key bonds, isolating intermediates, and purifying the final product, aiming to improve yield, reduce impurities, avoid hazardous reagents, or simplify manufacturing. These patents usually list defined starting materials, reaction conditions, catalysts/solvents, temperatures, times, workup, and purification methods—features that are central to “process” claims rather than “product” claims.
How process patents differ from abrocitinib substance (API) patents
Substance (API) patents claim abrocitinib as a compound and cover compositions of matter. Process patents instead claim methods of manufacturing abrocitinib (often including particular intermediates and their preparation). Even if an API patent expires, specific process patents may still limit certain manufacturing routes if those routes match the claimed steps and conditions.
What to look for when searching for abrocitinib process synthesis patents
When you search, focus on the parts of a document that signal a manufacturing route claim:
- Method/“process” language in the claims (e.g., “A method of preparing abrocitinib comprising….”).
- Named intermediates and their preparation steps (often with exact structures or identifiers).
- Specific reaction types used in the route (for example, reductions, coupling steps, nitration/halogenation, or cyclization if present in the route).
- Purification claims that reference crystallization conditions (solvent system, seeding, temperatures) and control of specific impurities.
If you share a patent number, assignee/company name, or a country/region (US, EP, WO/WO publication), I can help interpret what that exact patent’s process claims cover.
Why process synthesis patents matter to manufacturers
Companies may need process licenses (or non-infringing design-arounds) if they want to produce abrocitinib using a route that matches patented steps. Process patents can also affect:
- Contract manufacturing choices (which route the CMOs are licensed or tooled to run).
- Tech transfer and batch reproducibility (claimed conditions must be met or avoided).
- Clearance for generics/biosimilar-like “manufacturing” challenges (where relevant to small-molecule generics).
Which jurisdictions usually publish these filings (and how they’re indexed)
Abrocitinib process patents are commonly published through:
- WO (PCT) publications (international family starting point),
- national filings in the US (USPTO), Europe (EPO), China (CNIPA), etc.,
with claim language and added national details varying by office. Patent databases often index these under abrocitinib plus terms like “preparation,” “process,” “manufacturing,” “intermediate,” “crystallization,” or using the intermediate names/structures.
Risks and “design-around” angles in process patents
If a manufacturer wants to avoid infringement, design-around efforts typically target:
- substituting one intermediate for another,
- changing key reagents/catalysts,
- altering temperature/time regimes,
- switching solvent systems or purification/crystallization conditions,
- changing the order of steps where the claim is step-sequencing specific.
Because claims can be narrow or broad, a careful claim-by-claim reading is usually required.
If you want the exact patent(s), what details to provide
To find and summarize the correct “abrocitinib process synthesis” patent(s), share any of the following:
- a patent number (e.g., WO20xx… / US20… / EP…),
- the assignee/company name,
- the publication country/region,
- the intermediate name(s) mentioned,
- or paste claim text / a link.
With that, I can extract what the process claims cover, identify the critical steps/conditions, and explain how they differ from the API-substance claims.
Sources
No sources were provided with the prompt, so I did not cite any.